-
LIXIANA® ▼ (edoxaban) shows reduced rate of a variety of types of intracranial haemorrhage compared to warfarin in new sub-analysis presented at the European Stroke Organisation Conference 2018Daiichi Sankyo2020-08-03 09:38:26LIXIANA® ▼ (edoxaban) shows reduced rate of a variety of types of intracranial haemorrhage compared to
-
Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual MeetingDaiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and
-
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific AntibodiesDaiichi Sankyo2018-11-15 08:38:42Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
-
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)Daiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with
-
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target InitiativeDaiichi Sankyo2019-12-11 10:35:57Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
-
Daiichi Sankyo’s HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLWDaiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo’s HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric
-
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal CancerDaiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
-
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung CancerDaiichi Sankyo2018-02-22 19:00:01Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
-
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung CancerDaiichi Sankyo2018-02-06 16:00:01Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung
-
Daiichi Sankyo Reports on Practical Implications of Advances and Challenges in Oral AnticoagulationDaiichi Sankyo2020-08-03 09:39:00Daiichi Sankyo Reports on Practical Implications of Advances and Challenges in Oral Anticoagulation
